MTOR and cancer: SGLT2 inhibitors hinder the proliferation of cancer cells and their metabolic reprogramming through a variety of means, including downregulating the Wnt/β-catenin pathway, activating AMPK, inducing ferroptosis, and suppressing mTOR.